• 1
    Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006; 130: 148091.
  • 2
    Drossman DA, Morris CB, Hu Y et al. A prospective assessment of bowel habit in irritable bowel syndrome in women: defining an alternator. Gastroenterology 2005; 128: 5809.
  • 3
    Mearin F, Balboa A, Badia X et al. Irritable bowel syndrome subtypes according to bowel habit: revisiting the alternating subtype. Eur J Gastroenterol Hepatol 2003; 15: 16572.
  • 4
    Hungin AP, Whorwell PJ, Tack J, Mearin F. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40 000 subjects. Aliment Pharmacol Ther 2003; 17: 64350.
  • 5
    Spiller RC, Meyers NL, Hickling RI. Identification of patients with non-d, non-C irritable bowel syndrome and treatment with renzapride: an exploratory, multicenter, randomized, double-blind, placebo-controlled clinical trial. Dig Dis Sci 2008; 53: 3191200.
  • 6
    Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012; 10: 71221, e4.
  • 7
    Drossman DA, Corazziari E, Talley NJ, Thompson GW, Whitehead WE. Rome II: The Functional Gastrointestinal Disorders. McLean: Degnon Associates Inc, 2000.
  • 8
    O'Donnell LJ, Virjee J, Heaton KW. Detection of pseudodiarrhoea by simple clinical assessment of intestinal transit rate. BMJ 1990; 300: 43940.
  • 9
    Probert CS, Emmett PM, Cripps HA, Heaton KW. Evidence for the ambiguity of the term constipation: the role of irritable bowel syndrome. Gut 1994; 35: 14558.
  • 10
    Tillisch K, Labus JS, Naliboff BD et al. Characterization of the alternating bowel habit subtype in patients with irritable bowel syndrome. Am J Gastroenterol 2005; 100: 896904.
    Direct Link:
  • 11
    Schmulson M, Vargas JA, Lopez-Colombo A, Remes-Troche JM, Lopez-Alvarenga JC. [Prevalence and clinical characteristics of the IBS subtypes according to the Rome III criteria in patients from a clinical, multicentric trial. A report from the Mexican IBS Working Group.]. Rev Gastroenterol Mex 2010; 75: 42738.
  • 12
    Yao X, Yang YS, Cui LH et al. Subtypes of irritable bowel syndrome on Rome III criteria: a multicenter study. J Gastroenterol Hepatol 2012; 27: 7605.
  • 13
    Jamali R, Jamali A, Poorrahnama M et al. Evaluation of health related quality of life in irritable bowel syndrome patients. Health Qual Life Outcomes 2012; 10: 12.
  • 14
    Chey WD, Pare P, Viegas A, Ligozio G, Shetzline MA. Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial. Am J Gastroenterol 2008; 103: 121725.
    Direct Link:
  • 15
    Guidance for Industry Irritable Bowel Syndrome — Clinical Evaluation of Drugs for Treatment. In: U.S. Department of Health and Human Services FaDA, Center for Drug Evaluation and Research (CDER), eds. Silver Spring: U.S. Food and Drug Administration, 2012.
  • 16
    Talley NJ, Phillips SF, Melton J 3rd, Wiltgen C, Zinsmeister AR. A patient questionnaire to identify bowel disease. Ann Intern Med 1989; 111: 6714.
  • 17
    Rosenstiel AK, Keefe FJ. The use of coping strategies in chronic low back pain patients: relationship to patient characteristics and current adjustment. Pain 1983; 17: 3344.
  • 18
    Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 36170.
  • 19
    Kroenke K, Spitzer RL, Williams JB. The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. Psychosom Med 2002; 64: 25866.
  • 20
    Labus JS, Mayer EA, Chang L, Bolus R, Naliboff BD. The central role of gastrointestinal-specific anxiety in irritable bowel syndrome: further validation of the visceral sensitivity index. Psychosom Med 2007; 69: 8998.
  • 21
    Ware J, Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996; 34: 22033.
  • 22
    Ware JE, Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 47383.
  • 23
    Weinland SR, Morris CB, Hu Y, Leserman J, Bangdiwala SI, Drossman DA. Characterization of episodes of irritable bowel syndrome using ecological momentary assessment. Am J Gastroenterol 2011; 106: 181320.
  • 24
    Bijkerk CJ, de Wit NJ, Stalman WA, Knottnerus JA, Hoes AW, Muris JW. Irritable bowel syndrome in primary care: the patients' and doctors' views on symptoms, etiology and management. Can J Gastroenterol 2003; 17: 3638; quiz 405–6.
  • 25
    Ringel Y, Williams RE, Kalilani L, Cook SF. Prevalence, characteristics, and impact of bloating symptoms in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2009; 7: 6872; quiz 3.
  • 26
    Lembo T, Naliboff B, Munakata J et al. Symptoms and visceral perception in patients with pain-predominant irritable bowel syndrome. Am J Gastroenterol 1999; 94: 13206.
    Direct Link:
  • 27
    Schmulson M, Lee OY, Chang L, Naliboff B, Mayer EA. Symptom differences in moderate to severe IBS patients based on predominant bowel habit. Am J Gastroenterol 1999; 94: 292935.
    Direct Link:
  • 28
    Palsson OS, Baggish JS, Turner MJ, Whitehead WE. IBS patients show frequent fluctuations between loose/watery and hard/lumpy stools: implications for treatment. Am J Gastroenterol 2012; 107: 28695.
  • 29
    Manning AP, Wyman JB, Heaton KW. How trustworthy are bowel histories? Comparison of recalled and recorded information. Br Med J 1976; 2: 2134.